Biomarkers of the Metabolic Syndrome and Breast Cancer Prognosis

Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China. .
Cancers 06/2010; 2(2):721-739. DOI: 10.3390/cancers2020721
Source: PubMed

ABSTRACT In spite of its public health importance, our understanding of the mechanisms of breast carcinogenesis and progress is still evolving. The metabolic syndrome (MS) is a constellation of biochemical abnormalities including visceral adiposity, hyperglycemia, hyperinsulinemia, dyslipidemia and high blood pressure. The components of the MS have all been related to late-stage disease and even to a poor prognosis of breast cancer through multiple interacting mechanisms. In this review, we aim to present a summary of recent advances in the understanding of the contribution of the MS to breast cancer with the emphasis on the role of biomarkers of the MS in the prognosis of breast cancer.


Available from: Meng-Hua Tao, Sep 09, 2014